<br><br><div class="gmail_quote">On Thu, Jun 24, 2010 at 6:23 AM, Max More <span dir="ltr"><<a href="mailto:max@maxmore.com">max@maxmore.com</a>></span> wrote:<br><blockquote class="gmail_quote" style="margin: 0pt 0pt 0pt 0.8ex; border-left: 1px solid rgb(204, 204, 204); padding-left: 1ex;">
<a href="http://www.msnbc.msn.com/id/37881663/ns/health-health_care/" target="_blank">http://www.msnbc.msn.com/id/37881663/ns/health-health_care/</a><br>
<br>
_______________________________________________<br>
extropy-chat mailing list<br>
<a href="mailto:extropy-chat@lists.extropy.org" target="_blank">extropy-chat@lists.extropy.org</a><br>
<a href="http://lists.extropy.org/mailman/listinfo.cgi/extropy-chat" target="_blank">http://lists.extropy.org/mailman/listinfo.cgi/extropy-chat</a><br>
</blockquote></div><br><br>What really frustrates me is that we see stories like this coming out of basic research every day, and yet frontline treatment never seem to substantially advance as a result. The disconnect between what's happening in the lab, and begin trialled on a small scale, and what is available to the general population, seems to be getting larger.<br>
<br>Ross<br>